Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
6 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to InMed Pharmaceuticals Inc.’s names, not what it holds today.
Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 3 in 2024 and 1 in 2023
Applications published
14
since 2001, to Dec 31, 2025
Names they are printed under
4
a subsidiary, its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
BayMedica, Inc. a subsidiary
named as the applicant on its applications, in US
7 publishedINMED PHARMACEUTICALS INC. its own name
named as the applicant on its applications, in CA
7 publishedINMED PHARMACEUTICALS INC. its own name
CA, as the owner printed on each patent
0 publishedBayMedica, Inc. a subsidiary
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 15, 2025 | 12,357,604 | Topical formulations of cannabinoids and use thereof in the treatment of pain | Pharmaceuticals | INMED PHARMACEUTICALS INC. |
| Sep 10, 2024 | 12,083,229 | Ocular drug delivery formulation | Pharmaceuticals | INMED PHARMACEUTICALS INC. |
| Sep 3, 2024 | 12,077,802 | Metabolic engineering of E. coli for the biosynthesis of cannabinoid | Biotechnology | INMED PHARMACEUTICALS INC. |
| Jul 23, 2024 | 12,042,479 | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | Pharmaceuticals | INMED PHARMACEUTICALS INC. |
| Jan 17, 2023 | 11,555,211 | Recombinant production systems for prenylated polyketides of the cannabinoid family | Biotechnology | BayMedica, Inc. |
| Nov 17, 2020 | 10,837,031 | Recombinant production systems for prenylated polyketides of the cannabinoid family | Biotechnology | BayMedica, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Apr 11, 2024 | 2024/0117388 | ACYL ACTIVATING ENZYMES FOR PREPARATION OF CANNABINOIDS | Biotechnology | BayMedica, Inc. |
| Nov 30, 2023 | 2023/0381205 | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS | Pharmaceuticals | INMED PHARMACEUTICALS INC. |
| Mar 2, 2023 | 2023/0063862 | PREPARATION OF CANNABICHROMENE AND RELATED CANNABINOIDS | Organic fine chemistry | BayMedica, Inc. |
| Mar 2, 2023 | 2023/0063396 | GENETICALLY MODIFIED YEAST FOR THE PRODUCTION OF CANNABIGEROLIC ACID, CANNABICHROMENIC ACID AND RELATED CANNABINOIDS | Biotechnology | BayMedica, Inc. |
| Feb 9, 2023 | 2023/0043428 | COMPOSITIONS AND METHODS FOR USE OF CANNABINOIDS FOR NEUROPROTECTION | Pharmaceuticals | INMED PHARMACEUTICALS INC. |
| Jun 2, 2022 | 2022/0170056 | COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF TERPENOIDS OR CANNABINOIDS IN A HETEROLOGOUS SYSTEM | Biotechnology | INMED PHARMACEUTICALS INC. |
| Dec 30, 2021 | 2021/0403959 | USE OF TYPE I AND TYPE II POLYKETIDE SYNTHASES FOR THE PRODUCTION OF CANNABINOIDS AND CANNABINOID ANALOGS | Biotechnology | BayMedica, Inc. |
| Dec 30, 2021 | 2021/0403408 | CANNABINOID ANALOGS AND METHODS FOR THEIR PREPARATION | Organic fine chemistry | BayMedica, Inc. |
| Feb 11, 2021 | 2021/0040512 | RECOMBINANT PRODUCTION SYSTEMS FOR PRENYLATED POLYKETIDES OF THE CANNABINOID FAMILY | Biotechnology | BayMedica, Inc. · patent 11,555,211 granted from it |
| Sep 17, 2020 | 2020/0291434 | METABOLIC ENGINEERING OF E. COLI FOR THE BIOSYNTHESIS OF CANNABINOID PRODUCTS | Biotechnology | INMED PHARMACEUTICALS INC. · patent 12,077,802 granted from it |
What it applied for, 2024 to 2025: Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.